Celerion has expanded its formal business presence in Singapore, and has named Dr. Chew Lan Chong, MBBS, MRCS, MSc, executive director, medical research, of its new operations. Chong has 10 years of direct operational experience leading clinical pharmacology units.
The opening of the Singapore operations follows the recent announcement of Celerion’s expansion into South Korea, opening clinical operations at Seoul National University Hospital (SNUH) Clinical Trial Center and collaborating with the Korean Drug Development Fund (KDDF).
The expansion to Singapore and South Korea enables Celerion to provide access for clients to perform innovative and informative early clinical research studies in Asian patients and healthy participants. Through Celerion, clients will have access to patient populations suitable for participation in early clinical research in oncology, hepatitis B, cardiovascular (atherosclerosis and hypertension), diabetes, arthritis, osteoporosis, pain, psychiatric conditions, Alzheimer’s disease, Parkinson’s disease, asthma and COPD. In addition, Celerion’s partners will provide experience in pharmacogenetics and ethnic bridging studies in Asian populations.
Chong will lead Celerion’s business operations in Singapore, provide medical and scientific expertise and collaborate with early clinical research units to conduct complex early clinical pharmacology studies to global standards.